WILMINGTON, MA, May 14, 2012 (MARKETWIRE via COMTEX) --Showing further traction in the growing market for security
equipment in China, Implant Sciences Corporation (OTCQB: IMSC)
(PINKSHEETS: IMSC), a high technology supplier of systems and sensors
for homeland security and defense markets, today announced it has
shipped orders worth approximately $150,000 of its Quantum
Sniffer(TM) QS-H150 handheld explosives detectors to customers in
China. The QS-H150s are to be deployed by Chinese police and military
for security inspection and bomb squad applications.
"We continue to have a significant market presence in China where our
QS-H150 is regarded as one of the top trace detectors on the market,"
stated Glenn D. Bolduc, President and CEO of Implant Sciences. "This
sale comes through our in-country service provider, Beijing Ritchie
Link Technology, which is providing superior aftermarket service for
our growing installed base of customers, leading to repeat sales and
sales to new customers."
About the Quantum Sniffer(TM) QS-H150
The QS-H150 is a handheld explosives trace detector that uses Ion
Mobility Spectrometry (IMS) to rapidly detect and identify trace
amounts of a wide variety of military, commercial, and homemade
explosives. The QS-H150 uses no radioactive materials and features a
low-maintenance design that is self-calibrating and self-clearing,
providing very high levels of operational availability.
About the Quantum Sniffer(TM) QS-B220
The QS-B220, introduced in May 2011, is a benchtop explosives and
narcotics trace detector that uses Ion Mobility Spectrometry (IMS) to
rapidly detect and identify trace amounts of a wide variety of
military, commercial, and homemade explosives, plus narcotic
substances. The QS-B220 continues the Implant Sciences tradition of
freedom from radioactive materials, low total cost of ownership, and
high operational availability.
About Implant Sciences
Implant Sciences develops, manufactures and sells sophisticated
sensors and systems for Security, Safety, and Defense (SS&D) markets.
The Company has developed proprietary technologies used in its
commercial explosive and narcotics trace detection systems which ship
to a growing number of locations domestically and internationally.
Implant Sciences' QS-H150 portable explosives trace detector has
received Qualified Anti-Terrorism Technology Designation and the
Company's QS-B220 benchtop explosives and narcotics trace detector
has received a Developmental Testing & Evaluation (DT&E) Designation
by the U.S. Department of Homeland Security under the Support
Anti-terrorism by Fostering Effective Technology Act of 2002 (the
SAFETY Act). For further details on the Company and its products,
please visit the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking statements,"
as that term is defined in the Private Securities Litigation Reform
Act of 1995. Such statements are based on management's current
expectations and are subject to risks and uncertainties that could
cause the Company's actual results to differ materially from the
forward-looking statements. Such risks and uncertainties include, but
are not limited to, the risks that our explosives detection products
and technologies (including any new products we may develop) may not
be accepted by the Transportation Security Administration or by other
U.S. or foreign government and law enforcement agencies or commercial
consumers of security products; economic, political and other risks
associated with international sales and operations could adversely
affect our sales; our business is subject to intense competition and
rapid technological change; the risks that our markets are subject to
technological change and that our success depends on our ability to
develop and introduce new products; that our success depends on our
ability to obtain new patents and operate without infringing on the
proprietary rights of others; that we may not obtain the patents we
have applied for; that the validity and breadth of claims in
technology patents involve complex legal and factual questions and,
therefore, may be highly uncertain; that any patents we may obtain
may be may be challenged and subsequently invalidated, that we may
incur substantial costs in asserting our patent rights; and other
risks and uncertainties described in our filings with the Securities
and Exchange Commission, including its most recent Forms 10-K, 10-Q
and 8-K. Such statements are based on management's current
expectations and assumptions which could differ materially from the
Implant Sciences Corporation
SOURCE: Implant Sciences Corporation